Signature HealthCARE Facilities Ranked as America’s Best in Newsweek 2022 Survey
25 janv. 2022 13h17 HE
|
Signature Healthcare
Louisville, Ky., Jan. 25, 2022 (GLOBE NEWSWIRE) -- In the ever-changing environment of long-term care during our nation’s on-going pandemic, the balance between enduring and thriving is a daunting...
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
25 janv. 2022 06h45 HE
|
BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
25 janv. 2022 06h45 HE
|
BioNTech SE
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
Everstream Analytics Supply Chain Risk Solutions Now Available on Oracle Cloud Marketplace
24 janv. 2022 10h00 HE
|
Everstream Analytics
SAN MARCOS, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Everstream Analytics, a leading provider of Supply Chain Risk Analytics and a member of Oracle PartnerNetwork (OPN), today announced that...
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
24 janv. 2022 06h00 HE
|
SAB Biotherapeutics, Inc.
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700...
Given the Current Testing Restraints, Luxor Scientific Reiterates Excess Capacity for COVID-19 Testing
19 janv. 2022 14h02 HE
|
Luxor Scientific, LLC.
GREENVILLE, S.C., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Luxor Scientific, a full-service clinical testing laboratory that provides laboratory services nationally and for individuals within the region,...
Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology
18 janv. 2022 07h30 HE
|
Achiko AG
ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post:...
Achiko AG Reports Breakthrough Calibration Results for its AptameX™ Covid-19 Rapid Test Technology
14 janv. 2022 07h30 HE
|
Achiko AG
AptameX™ Covid-19 rapid calibration successfully classified 100% of results indicatinga likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.Results were...
Adagio Therapeutics总结了ADG20对新冠病毒变种的中和活性,并概述了应对奥密克戎的举措
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
几家独立实验室最近发表的文章表明,ADG20具有中和活性,其效力可与其他针对奥密克戎的保有活性抗体相媲美 目前正在进行多项努力来应对奥密克戎和潜在的新冠病毒变种 马萨诸塞州沃尔瑟姆, Jan. 14, 2022 (GLOBE NEWSWIRE) -- 专注于发现、开发和商业化具有疫情潜力传染病抗体解决方案的临床阶段生物制药公司Adagio Therapeutics,...
Adagio Therapeutics Meringkaskan Aktiviti Peneutralan ADG20 Terhadap Varian SARS-CoV-2 dan Menggariskan Inisiatif Menangani Omicron
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Penerbitan Terkini oleh Beberapa Makmal Bebas Menunjukkan ADG20 Mempunyai Aktiviti Yang Meneutralkan dengan Potensi Setanding dengan Antibodi Lain yang Mengekalkan Aktiviti Melawan Omicron Pelbagai...